

# Rikke Hedegaard Dahlrot

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/7917486/rikke-hedegaard-dahlrot-publications-by-citations.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

41  
papers

1,262  
citations

20  
h-index

35  
g-index

43  
ext. papers

1,602  
ext. citations

3.1  
avg, IF

4.67  
L-index

#	Paper	IF	Citations
41	Tumour-associated microglia/macrophages predict poor prognosis in high-grade gliomas and correlate with an aggressive tumour subtype. <i>Neuropathology and Applied Neurobiology</i> , <b>2018</b> , 44, 185-206	5.2	105
40	MiR-21 expression in the tumor cell compartment holds unfavorable prognostic value in gliomas. <i>Journal of Neuro-Oncology</i> , <b>2013</b> , 111, 71-81	4.8	80
39	STEM-13 EXPRESSION OF STEM CELL, PROLIFERATION AND CHEMORESISTANCE MARKERS IN GLIOMA CELLS IN THE TUMOR PERIPHERY. <i>Neuro-Oncology</i> , <b>2015</b> , 17, v210.5-v211	1	78
38	TMIC-18 TUMOR-ASSOCIATED MICROGLIA/MACROPHAGES ARE ASSOCIATED WITH POOR PROGNOSIS IN HIGH-GRADE GLIOMAS AND CONTRIBUTE TO THE GLIOBLASTOMA STEM CELL-LIKE NICHE. <i>Neuro-Oncology</i> , <b>2015</b> , 17, v218.6-v218	1	78
37	GENE-33. INTEGRATED GLIOMA DIAGNOSTICS USING TARGETED NEXT-GENERATION SEQUENCING. <i>Neuro-Oncology</i> , <b>2019</b> , 21, vi104-vi104	1	78
36	P04.25 Expression and prognostic value of the transcription factors EGR1 and EGR3 in gliomas. <i>Neuro-Oncology</i> , <b>2018</b> , 20, iii284-iii284	1	78
35	P01.114 Expression and prognostic value of the immune checkpoint molecule galectin-9 in glioblastomas. <i>Neuro-Oncology</i> , <b>2018</b> , 20, iii257-iii258	1	78
34	P01.083 Expression and prognostic value of the immune checkpoint molecule galectin-9 in glioblastomas. <i>Neuro-Oncology</i> , <b>2018</b> , 20, iii249-iii249	1	78
33	P04.41 Expression and prognostic value of the transcription factors EGR1 and EGR3 in gliomas. <i>Neuro-Oncology</i> , <b>2018</b> , 20, iii288-iii288	1	78
32	High-throughput flow cytometry screening reveals a role for junctional adhesion molecule a as a cancer stem cell maintenance factor. <i>Cell Reports</i> , <b>2014</b> , 6, 117-29	10.6	61
31	What is the clinical value of cancer stem cell markers in gliomas?. <i>International Journal of Clinical and Experimental Pathology</i> , <b>2013</b> , 6, 334-48	1.4	57
30	High levels of c-Met is associated with poor prognosis in glioblastoma. <i>Journal of Neuro-Oncology</i> , <b>2015</b> , 122, 517-27	4.8	47
29	Expression and prognostic value of the WEE1 kinase in gliomas. <i>Journal of Neuro-Oncology</i> , <b>2016</b> , 127, 381-9	4.8	39
28	Clinical value of CD133 and nestin in patients with glioma: a population-based study. <i>International Journal of Clinical and Experimental Pathology</i> , <b>2014</b> , 7, 3739-51	1.4	39
27	Prognostic value of Musashi-1 in gliomas. <i>Journal of Neuro-Oncology</i> , <b>2013</b> , 115, 453-61	4.8	36
26	Transferrin receptor-1 and ferritin heavy and light chains in astrocytic brain tumors: Expression and prognostic value. <i>PLoS ONE</i> , <b>2017</b> , 12, e0182954	3.7	36
25	A population-based study of low-grade gliomas and mutated isocitrate dehydrogenase 1 (IDH1). <i>Journal of Neuro-Oncology</i> , <b>2013</b> , 114, 309-17	4.8	29

24	A population-based study of high-grade gliomas and mutated isocitrate dehydrogenase 1. <i>International Journal of Clinical and Experimental Pathology</i> , <b>2013</b> , 6, 31-40	1.4	28
23	Glioma Cells in the Tumor Periphery Have a Stem Cell Phenotype. <i>PLoS ONE</i> , <b>2016</b> , 11, e0155106	3.7	21
22	Prognostic value of O-6-methylguanine-DNA methyltransferase (MGMT) protein expression in glioblastoma excluding nontumour cells from the analysis. <i>Neuropathology and Applied Neurobiology</i> , <b>2018</b> , 44, 172-184	5.2	20
21	Quality of life in patients with cancer during the COVID-19 pandemic - a Danish cross-sectional study (COPICADS). <i>Acta Oncologica</i> , <b>2021</b> , 60, 4-12	3.2	15
20	Evaluation of the proliferation marker Ki-67 in gliomas: Interobserver variability and digital quantification. <i>Diagnostic Pathology</i> , <b>2018</b> , 13, 38	3	14
19	The prognostic value of clinical factors and cancer stem cell-related markers in gliomas. <i>Danish Medical Journal</i> , <b>2014</b> , 61, B4944	3.8	14
18	Plan quality for high-risk prostate cancer treated with high field magnetic resonance imaging guided radiotherapy. <i>Physics and Imaging in Radiation Oncology</i> , <b>2018</b> , 7, 1-8	3.1	11
17	Development and validation of a prognostic model for recurrent glioblastoma patients treated with bevacizumab and irinotecan. <i>Acta Oncologica</i> , <b>2016</b> , 55, 418-22	3.2	10
16	Trends in tumors in the central nervous system in elderly in Denmark, 2008-2012. <i>Acta Oncologica</i> , <b>2016</b> , 55 Suppl 1, 91-7	3.2	9
15	Posttreatment Effect of MGMT Methylation Level on Glioblastoma Survival. <i>Journal of Neuropathology and Experimental Neurology</i> , <b>2019</b> , 78, 633-640	3.1	8
14	Expression and prognostic value of JAM-A in gliomas. <i>Journal of Neuro-Oncology</i> , <b>2017</b> , 135, 107-117	4.8	8
13	Novel approaches for quantifying protein biomarkers in gliomas: benefits and pitfalls. <i>CNS Oncology</i> , <b>2014</b> , 3, 287-98	4	8
12	APNG as a prognostic marker in patients with glioblastoma. <i>PLoS ONE</i> , <b>2017</b> , 12, e0178693	3.7	8
11	Targeted next-generation sequencing of adult gliomas for retrospective prognostic evaluation and up-front diagnostics. <i>Neuropathology and Applied Neurobiology</i> , <b>2021</b> , 47, 108-126	5.2	3
10	Aberrant neuronal differentiation is common in glioma but is associated neither with epileptic seizures nor with better survival. <i>Scientific Reports</i> , <b>2018</b> , 8, 14965	4.9	3
9	Evolution of the gross tumour volume extent during radiotherapy for glioblastomas. <i>Radiotherapy and Oncology</i> , <b>2021</b> , 160, 40-46	5.3	3
8	Study protocol for OptimalTTF-2: enhancing Tumor Treating Fields with skull remodeling surgery for first recurrence glioblastoma: a phase 2, multi-center, randomized, prospective, interventional trial. <i>BMC Cancer</i> , <b>2021</b> , 21, 1010	4.8	2
7	A national study on the inter-observer variability in the delineation of organs at risk in the brain. <i>Acta Oncologica</i> , <b>2021</b> , 60, 1548-1554	3.2	1

6	Prognostic role of Ki-67 in glioblastomas excluding contribution from non-neoplastic cells. <i>Scientific Reports</i> , <b>2021</b> , 11, 17918	4.9	1
5	Treatment plan comparison of proton vs photon radiotherapy for lower-grade gliomas. <i>Physics and Imaging in Radiation Oncology</i> , <b>2021</b> , 20, 98-104	3.1	0
4	Metastatic atypical renal tumour with metanephric characteristics treated with Sunitinib. <i>Urology Case Reports</i> , <b>2022</b> , 40, 101880	0.5	0
3	Determining viability of using APNG status as a prognostic marker in patients with glioblastoma multiforme.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 2028-2028	2.2	
2	C-met, a new prognostic biomarker in glioblastoma multiforme.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 2088-2088	2.2	
1	P14.69 Trends in postoperative chemoradiotherapy for Glioblastoma patients: a Danish cohort study. <i>Neuro-Oncology</i> , <b>2021</b> , 23, ii51-ii51	1	